Nasu-Hakola disease (NHD), also known as polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), is a rare autosomal recessive disorder caused by mutations in TREM2 or TYROBP genes[^1]. This disease uniquely connects microglial dysfunction to both bone and brain pathology, making it a crucial model for understanding microglia-mediated neurodegeneration.
| Property |
Value |
| Category |
Immune Cells |
| Location |
Brain parenchyma, bone marrow |
| Cell Type |
Activated microglia, osteoclasts |
| Key Genes |
TREM2, TYROBP (DAP12) |
| Inheritance |
Autosomal recessive |
| Prevalence |
<1:1,000,000 |
¶ Genetics and Molecular Pathogenesis
- Location: Chromosome 6p21.1
- Protein: Triggering receptor expressed on myeloid cells 2
- Function: Lipid sensing receptor on microglia
- Effect: Loss-of-function leads to impaired phagocytosis
- Location: Chromosome 19q13.12
- Protein: TYROBP (DAP12), adaptor protein
- Function: Signal transduction for TREM2
- Effect: Disrupts TREM2 signaling cascade
- Ligand binding: TREM2 binds lipids, apolipoproteins
- Signal transduction: TYROBP activates ITAM pathway
- Cellular responses: Phagocytosis, cytokine production, survival
- Dysfunction: Impaired lipid sensing and clearance
- Immune surveillance: Continuous process monitoring
- Phagocytosis: Clearance of debris, dead cells, aggregates
- Synaptic pruning: Developmental and pathological remodeling
- Cytokine signaling: Inflammation modulation
- Support functions: Metabolic support, trophic factor release
TREM2 is critical for several microglial activities:
- Lipid metabolism: Sensing and processing myelin debris
- Amyloid clearance: Critical in Alzheimer's disease models
- Cell survival: Preventing apoptosis
- Proliferation: Response to brain injury
The TREM2/TYROBP pathway is essential for microglial lipid sensing and phagocytosis[^2]:
- Myelin debris accumulation: Incomplete clearance
- Lipid droplet formation: Defective processing
- Lysosomal dysfunction: Autophagy impairment
- Cellular stress: ER stress, oxidative damage
- Cytokine dysregulation: Elevated IL-1β, TNF-α, IL-6
- Failed resolution: Persistent inflammatory state
- NLRP3 inflammasome: Hyperactivation
- White matter lesions: Sclerosing leukoencephalopathy
- Cerebral atrophy: Progressive brain volume loss
- Demyelination: Primary pathology
- Neuronal loss: Secondary to gliosis
The same genes affect osteoclasts:
- Bone cysts: Polycystic changes in long bones
- Premenopausal fractures: Pathological fractures
- Impaired remodeling: Defective osteoclast function
| Feature |
Onset |
Description |
| Bone cysts |
20-30 years |
Painless fractures |
| Psychiatric symptoms |
30-40 years |
Personality changes, disinhibition |
| Progressive dementia |
40-50 years |
Rapid cognitive decline |
| Motor symptoms |
50+ years |
Gait disturbance, paresis |
-
Anti-inflammatory therapy: Targeting cytokine pathways
- IL-1 antagonists (anakinra)
- TNF-α inhibitors
-
Bone marrow transplantation: Microglial replacement
-
Symptomatic treatment: Supportive care
- Cognitive enhancers
- Physical therapy
- TREM2 agonists: Small molecule activators
- Gene therapy: AAV-mediated TREM2 delivery
- Microglial replacement: iPSC-derived microglia
- Lipid metabolism modulators: Targeting the primary defect
- Biomarkers: CSF biomarkers for early detection
- Imaging: PET ligands for microglial activation
- Genotype-phenotype correlations: Variable expressivity
- Therapeutic windows: Early intervention potential
NHD provides insights into AD pathogenesis[^3]:
- TREM2 variants: AD risk factor (R47H, R62H)
- Microglial activation: Common pathway
- Lipid metabolism: Shared mechanisms
- Therapeutic translation: TREM2 as drug target
- Trem2 knockout mice: Microglial dysfunction
- Tyrobp knockout mice: Similar phenotype
- Human iPSC models: Patient-derived microglia
- Conditional knockouts: Cell-type specific studies
The study of Microglia In Nasu Hakola Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Paloneva J, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Nat Genet. 2002;31(1):21-22.
- Klunemann HH, et al. The genetic causes of frontotemporal degeneration and their therapeutic implications. Nat Rev Neurol. 2022;18(12):717-733.
- Griciuc A, et al. TREM2 deficiency impairs cholesterol metabolism and leads to neurodegeneration. Neuron. 2019;104(5):912-925.
- Kleinberger G, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6(243):243ra86.